Skip to main content
Erschienen in: Investigational New Drugs 1/2009

01.02.2009 | PHASE II STUDIES

Docetaxel and epirubicin salvage regimen in relapsed anthracycline-sensitive metastatic breast cancer patients after anthracycline-containing adjuvant therapy

verfasst von: Jae Hong Seo, Hwa Jung Sung, Kyong Hwa Park, In Keun Choi, Sang Cheul Oh, Sang Won Shin, Yeul Hong Kim, Jun Suk Kim, Ae-Ree Kim, Jae-Bok Lee, Bum Hwan Koo

Erschienen in: Investigational New Drugs | Ausgabe 1/2009

Einloggen, um Zugang zu erhalten

Summary

Our aim in this paper is to verify the efficacy and safety of a epirubicin and docetaxel salvage regimen for anthracycline sensitive metastatic breast cancer patients who have relapsed after anthracycline-containing adjuvant therapy. Thirty-two metastatic breast cancer patients were treated with epirubicin and docetaxel every 21 days. Of the 31 evaluable patients, there were 13/31 (41.9%) partial responses and no complete responses. Median time to progression was 12 months (95% CI, 4–60 months) and median survival duration was 41 months (95% CI, 1.2–80.8 months). According to the Cox model, ECOG performance and response group were statistically significant variables, and visceral metastasis was a borderline significant variable with regards to overall survival. Although this salvage regimen showed a high rate of hematologic toxicities, it was a relatively active regimen with manageable toxicities and no cardiac dysfunction. We propose that this salvage regimen could be carefully used in anthracycline sensitive metastatic breast cancer patients who have relapsed after anthracycline-containing adjuvant therapy.
Literatur
1.
Zurück zum Zitat Perez EA (1999) Current management of metastatic breast cancer. Semin Oncol 26:1–10PubMed Perez EA (1999) Current management of metastatic breast cancer. Semin Oncol 26:1–10PubMed
2.
Zurück zum Zitat Greenberg PA, Hortobagyi GN, Smith TL, Ziegler LD, Frye DK, Buzdar AU (1996) Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol 14:2197–2205PubMed Greenberg PA, Hortobagyi GN, Smith TL, Ziegler LD, Frye DK, Buzdar AU (1996) Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol 14:2197–2205PubMed
3.
Zurück zum Zitat Fossati R, Confalonieri C, Torri V, Ghislandi E, Penna A, Pistotti V et al (1998) Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women. J Clin Oncol 16:3439–3460PubMed Fossati R, Confalonieri C, Torri V, Ghislandi E, Penna A, Pistotti V et al (1998) Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women. J Clin Oncol 16:3439–3460PubMed
5.
Zurück zum Zitat Pacilio C, Morabito A, Nuzzo F, Gravina A, Labonia V, Landi G et al (2006) Is epirubicin effective in first-line chemotherapy of metastatic breast cancer (MBC) after an epirubicin-containing adjuvant treatment? A single centre phase III trial. Br J Cancer 94:1233–1236 doi:10.1038/sj.bjc.6603096 PubMedCrossRef Pacilio C, Morabito A, Nuzzo F, Gravina A, Labonia V, Landi G et al (2006) Is epirubicin effective in first-line chemotherapy of metastatic breast cancer (MBC) after an epirubicin-containing adjuvant treatment? A single centre phase III trial. Br J Cancer 94:1233–1236 doi:10.​1038/​sj.​bjc.​6603096 PubMedCrossRef
6.
7.
Zurück zum Zitat French Epirubicin Study Group (1988) A prospective randomized phase III trial comparing combination chemotherapy with cyclophosphamide, fluorouracil, and either doxorubicin or epirubicin. J Clin Oncol 6:679–688 French Epirubicin Study Group (1988) A prospective randomized phase III trial comparing combination chemotherapy with cyclophosphamide, fluorouracil, and either doxorubicin or epirubicin. J Clin Oncol 6:679–688
8.
Zurück zum Zitat Italian Multicentre Breast Study with Epirubicin (1988) Phase III randomized study of fluorouracil, epirubicin, and cyclophosphamide v fluorouracil, doxorubicin, and cyclophosphamide in advanced breast cancer: an Italian multicentre trial. J Clin Oncol 6:976–982 Italian Multicentre Breast Study with Epirubicin (1988) Phase III randomized study of fluorouracil, epirubicin, and cyclophosphamide v fluorouracil, doxorubicin, and cyclophosphamide in advanced breast cancer: an Italian multicentre trial. J Clin Oncol 6:976–982
9.
Zurück zum Zitat Bonadonna G, Gianni L, Santoro A, Bonfante V, Bidoli P, Casali P et al (1993) Drugs ten years later: epirubicin. Ann Oncol 4:359–369PubMed Bonadonna G, Gianni L, Santoro A, Bonfante V, Bidoli P, Casali P et al (1993) Drugs ten years later: epirubicin. Ann Oncol 4:359–369PubMed
10.
Zurück zum Zitat Cortes JE, Pazdur R (1995) Docetaxel. J Clin Oncol 13:2643–2655PubMed Cortes JE, Pazdur R (1995) Docetaxel. J Clin Oncol 13:2643–2655PubMed
11.
Zurück zum Zitat Valero V (1997) Docetaxel as single-agent therapy in metastatic breast cancer: clinical efficacy. Semin Oncol 24:S13–S18PubMed Valero V (1997) Docetaxel as single-agent therapy in metastatic breast cancer: clinical efficacy. Semin Oncol 24:S13–S18PubMed
15.
16.
Zurück zum Zitat Hainsworth JD, Yardley DA, Spigel DR, Meluch AA, Rinaldi D, Schnell FM et al (2006) Docetaxel and epirubicin as first-line treatment for patients with metastatic breast cancer: a Minnie Pearl Cancer Research Network Phase II trial. Cancer Invest 17:469–473 doi:10.1080/07357900600814060 CrossRef Hainsworth JD, Yardley DA, Spigel DR, Meluch AA, Rinaldi D, Schnell FM et al (2006) Docetaxel and epirubicin as first-line treatment for patients with metastatic breast cancer: a Minnie Pearl Cancer Research Network Phase II trial. Cancer Invest 17:469–473 doi:10.​1080/​0735790060081406​0 CrossRef
17.
Zurück zum Zitat Morales S, Lorenzo A, Ramos M, Ballesteros P, Mendez M, Almanza C et al (2004) Docetaxel plus epirubicin is a highly active, well-tolerated, first-line chemotherapy for metastatic breast cancer: results of a large, multicentre phase II study. Cancer Chemother Pharmacol 53:75–81PubMed Morales S, Lorenzo A, Ramos M, Ballesteros P, Mendez M, Almanza C et al (2004) Docetaxel plus epirubicin is a highly active, well-tolerated, first-line chemotherapy for metastatic breast cancer: results of a large, multicentre phase II study. Cancer Chemother Pharmacol 53:75–81PubMed
20.
Zurück zum Zitat Fabi A, Papaldo P, Pino MS, Ferretti G, Carlini P, Pacetti U et al (2004) Epirubicin plus docetaxel in metastatic breast cancer: escalating dose does not improve efficacy. A phase II study. Anticancer Res 24:1963–1967PubMed Fabi A, Papaldo P, Pino MS, Ferretti G, Carlini P, Pacetti U et al (2004) Epirubicin plus docetaxel in metastatic breast cancer: escalating dose does not improve efficacy. A phase II study. Anticancer Res 24:1963–1967PubMed
21.
Zurück zum Zitat Polyzos A, Tsavaris N, Kosmas C, Gogas H, Vadiaka M, Markopoulos C et al (2003) Docetaxel and epirubicin supported by granulocyte colony-stimulating factor first-line in advanced breast cancer. Anticancer Res 23:2917–2923PubMed Polyzos A, Tsavaris N, Kosmas C, Gogas H, Vadiaka M, Markopoulos C et al (2003) Docetaxel and epirubicin supported by granulocyte colony-stimulating factor first-line in advanced breast cancer. Anticancer Res 23:2917–2923PubMed
22.
Zurück zum Zitat Im SA, Kim SB, Lee MH, Im YH, Lee KH, Song HS et al (2005) Docetaxel plus epirubicin as first-line chemotherapy in MBC (KCSG 01-10-05): phase II trial and the predictive values of circulating HER2 extracellular domain and vascular endothelial growth factor. Oncol Rep 14:481–487PubMed Im SA, Kim SB, Lee MH, Im YH, Lee KH, Song HS et al (2005) Docetaxel plus epirubicin as first-line chemotherapy in MBC (KCSG 01-10-05): phase II trial and the predictive values of circulating HER2 extracellular domain and vascular endothelial growth factor. Oncol Rep 14:481–487PubMed
Metadaten
Titel
Docetaxel and epirubicin salvage regimen in relapsed anthracycline-sensitive metastatic breast cancer patients after anthracycline-containing adjuvant therapy
verfasst von
Jae Hong Seo
Hwa Jung Sung
Kyong Hwa Park
In Keun Choi
Sang Cheul Oh
Sang Won Shin
Yeul Hong Kim
Jun Suk Kim
Ae-Ree Kim
Jae-Bok Lee
Bum Hwan Koo
Publikationsdatum
01.02.2009
Verlag
Springer US
Erschienen in
Investigational New Drugs / Ausgabe 1/2009
Print ISSN: 0167-6997
Elektronische ISSN: 1573-0646
DOI
https://doi.org/10.1007/s10637-008-9151-2

Weitere Artikel der Ausgabe 1/2009

Investigational New Drugs 1/2009 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.